
Nov 27 2018 Cure EB joins consortium to fund anti-fibrotic treatment
We’re pleased to announce that Cure EB is joining three other EB charities to fund the clinical development of a new anti-fibrotic drug called TXA127.
Click to read press release from Constant Pharmaceuticals.